
Shares of InMed Pharmaceuticals Inc. climbed 21% to $1.87 during late-morning trading on the Nasdaq. Mentari Therapeutics, which is merging with InMed, revealed a $200 million private placement.
Today’s highest-ranked model selections.
The catalysts most likely to move markets.
This is the clearest scheduled U.S.-market price-discovery point today and can transmit weekend news into equity-index futures before Monday's cash session.
The Q2 retail package can move NZD and regional risk sentiment. Spillover to U.S. assets is usually secondary unless the result is unusually large.
The absence of U.S. releases, earnings, IPO pricings and split events leaves fewer scheduled catalysts, increasing the relative importance of weekend headlines and positioning at the futures reopen.